By Patricia Van Arnum, Pharmaceutical Technology.
Personalized medicine, which targets individualized treatment and care based on personal and genetic variations, holds much promise for the pharmaceutical industry. Several pharmaceutical majors continue to invest in this emerging field as evident by Roche’s $5.7-billion bid last week for Illumina, a provider of gene-sequencing tools and related analytics. Read More
New pharma supply chains, where chill control and traceability challenges will be far more critical, will emerge over the next decade, So it’s time, argues Julian Mosquera, for the industry to upgrade its capabilities.
Julian Mosquera
The pharmaceuticals industry is undergoing major disruption and every compar
ative benchmark indicates that the sector needs to make a step change in asset performance, with working capital targeted for direct improvement. All players are planning major reconfigurations of their supply and distribution operations, from end to end, in a bid to improve cost and service efficiency. This challenge is all the more prescient with a large number of blockbusters coming off patent over the next five years, opening the door to generic producers, who are actively “forging strategic alliances” to secure the rights to produce cheaper copies, according to researchers at Frost & Sullivan. While expenditure on new medicine has risen dramatically over the past decade, regulatory approval for new drugs has declined. Where big pharma could turn to blockbusters in the past, they are now looking to smarter portfolio management for competitive advantage.
Historical margins meant pharma paid little attention to their supply chains. However, over the last decade such complacency has become unacceptable to boards. Directors in the current environment are looking to their COOs and supply chain directors to build resilience into supply chain networks, to protect against market volatility and to drive real cost reduction. Read More
Forget illegal immigrants, it is machines that are stealing American jobs. For some medical practice areas, however, digital details haven’t sufficiently stepped in where their human sales rep predecessors have stepped (or have been pushed) out, according to a survey of U.S. physicians.
Even though Roche-owned Genentech wasn’t required to run costly corrective advertisements following an FDA Untitled Letter on Boniva last January, the company has done so anyway.
PharmExec Blog
Follow Us
RSS
Bookstore
PCORI, Priorities, and Politics
William Looney looks at the three P’s of effectiveness research: PCORI, Priorities, and Politics
If you ever wanted to know what health economists might do with a billion dollars, the Obama Administration’s Patient-Centered Outcomes Research Institute [PCORI] is about to tell all: not right down to the penny, but good enough. The congressionally funded – but independent – group has just released a document outlining priorities that will fuel a flood of research grants by mid-year. Application of that research will carry a significant impact on the evidence stream that increasingly determines Big Pharma’s access to providers and patients. Read More »